- Home
- ALLO vs MVF Comparison
ALLO vs MVF Comparison
Compare ALLO & MVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- MVF
- Stock Information
- Founded
- ALLO 2017
- MVF 1988
- Country
- ALLO United States
- MVF United States
- Employees
- ALLO N/A
- MVF N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- MVF Investment Bankers/Brokers/Service
- Sector
- ALLO Health Care
- MVF Finance
- Exchange
- ALLO Nasdaq
- MVF Nasdaq
- Market Cap
- ALLO 545.8M
- MVF 471.4M
- IPO Year
- ALLO 2018
- MVF N/A
- Fundamental
- Price
- ALLO $2.41
- MVF $7.44
- Analyst Decision
- ALLO Buy
- MVF
- Analyst Count
- ALLO 12
- MVF 0
- Target Price
- ALLO $10.26
- MVF N/A
- AVG Volume (30 Days)
- ALLO 1.6M
- MVF 162.8K
- Earning Date
- ALLO 10-31-2024
- MVF 01-01-0001
- Dividend Yield
- ALLO N/A
- MVF 4.11%
- EPS Growth
- ALLO N/A
- MVF N/A
- EPS
- ALLO N/A
- MVF N/A
- Revenue
- ALLO $65,000.00
- MVF N/A
- Revenue This Year
- ALLO N/A
- MVF N/A
- Revenue Next Year
- ALLO $6,292.80
- MVF N/A
- P/E Ratio
- ALLO N/A
- MVF N/A
- Revenue Growth
- ALLO 6.56
- MVF N/A
- 52 Week Low
- ALLO $2.01
- MVF $5.85
- 52 Week High
- ALLO $5.78
- MVF $7.19
- Technical
- Relative Strength Index (RSI)
- ALLO 43.24
- MVF 53.36
- Support Level
- ALLO $2.47
- MVF $7.37
- Resistance Level
- ALLO $2.64
- MVF $7.51
- Average True Range (ATR)
- ALLO 0.21
- MVF 0.07
- MACD
- ALLO -0.01
- MVF -0.01
- Stochastic Oscillator
- ALLO 22.95
- MVF 46.67
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.